Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of APSLXR in participants with Meniere's
disease or other Verigo of vestibular origin. Pharmacokinetics will also be evaluated in a
small group.